Company: IXHL
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001213900-25-036057
Chunk: 48

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 48
---
 |
| All Current Directors who are not executive officers as a group |     |    970,000 |
| Each other person who received 5% of such awards                |     |            |
| Troy Valentine, Chairperson                                     |     |    670,000 |
| All Employees who are not executive officers as a group         |     |     88,659 |

____________ (1)The named executive officers above include the most highly compensated executive officers other than our chief executive officer and our chief financial officer. In addition to the above referenced restricted stock units granted under the 2023 Plan, options to purchase an aggregate of 100,004shares of our common stock having a weighted -averageexercise price of $12.64 are held by Joel Latham, options to purchase an aggregate of 28,002shares of our common stock having a weighted -averageexercise price of 20.16 are held by Troy Valentine, options to purchase an aggregate of 3,000shares of our common stock having a weighted -averageexercise price of $20.16 are held by Joseph Swan and options to purchase an aggregate of 50,000shares of our common stock having a weighted -averageexercise price of $82.19 are held by Robert Clark, each of which was issued outside of the 2023 Plan prior to the Company’s November 28, 2023 the domiciliation from Australia to Delaware. The amounts of future awards under the Amended 2023 Plan are not determinable and will be granted at the sole discretion of the board of directors or the Committee, including grants to our named executive officers, our current executive officers, our current directors who are not executive officers, and employees who are not executive officers. On April 25, 2025, the closing market price per share of our common stock was $0.629 as reported by Nasdaq. Required Vote The affirmative vote of a majority of the shares of common stock present or represented by proxy and entitled to vote on the subject matter is required to approve this proposal. Abstentions will count as votes AGAINST this proposal. Broker non -voteswill have no effect on this proposal. Brokerage firms do not have authority to vote customers’ unvoted shares held by the firms in street name on this proposal. THE BOARD OF DIRECTORS RECOMMENDS APPROVAL OF THE AMENDMENTS TO THE 2023 EQUITY INCENTIVE PLAN TO INCREASE BY 2,700,000 SHARES THE AGGREGATE NUMBER OF SHARES